UNITAID NGO Delegation Expresses Strong Support for LDC Pharmaceutical Extension Request at WTO TRIPS Council
The NGO delegation to the Board of UNITAID offers its strong support for the proposal of WTO least developed country…
LDC Members’ Entitlement to and Need for a Further Extension of Their Pharmaceutical Transition Period
LDCs Members have submitted a duly motivated request for an unconditional extension of the 2002-2016 pharmaceutical transition period (covering patents…
The Dangers of the Indian Government’s Flirtation with U.S. Pharma and the Risks for India’s Coherent, Pro-Public Health IP Policy
[Cross posted from Equilibri.net] U.S. business interests and government officials are trying to sell the idea that heightened intellectual property protections…
Gilead’s Hepatitis C Medicines License – Troubling Territorial Exclusions, Illusory Exceptions, and Tiered Pricing Policy Fracture Global Access
Gilead has just released the text of its hepatitis C license. Although there has been some praise for Gilead offering…
Gilead’s Proposed Hepatitis C Medicines License: How Badly Will it Miss the Target?
Gilead has been busy building positive publicity for its proposed license on two new direct-acting oral antivirals used to treat…
MSF victorious in overcoming registration barrier to important 2d line treatment of DR-TB, but patent barrier may last a little bit longer
Médecins Sans Frontières has obtained an important but long-delayed victory in a a challenge to the refusal of the Medicines Control…
Released Text of GF Equitable Access Initiative Still Problemmatic
Mark Dybul, Executive Director of the Global Fund has written an email responding to a letter from 220 civil society…
Civil Society to the Global Fund: Abandon the Tiered-Pricing Initiative
Below is a communication sent by Civil Society Organizations to Mark Dybul and others calling for the abandonment of the…
Analysis of the ViiV/Medicines Patent Pool Dolutegravir Patent Licenses
This paper provides a detailed analysis of the effective geographical scope of the recently announced adult and pediatric between the…
Industry-Led Tiered-Pricing or Country-Led, Real Equitable Access – the Global Fund’s Task Force Proposal Get Worse Instead of Better
Professor Brook K. Baker, Northeastern U. School of Law Policy Analyst Health GAP Full Paper – PDF On or about…
Health GAP Response to PhRMA Submission for the Special 301 Review
[Brook Baker and Matt Kavanagh] Health GAP submits these comments in response to written and oral submissions made by PhRMA…
US’s “New” Proposed TPP Intellectual Property Chapter Still Requires Patents on Medicinal Forms With “Distinguishing Features”
The US has evergreened its patent proposal requiring patents on new forms of known/existing medicines by requiring patents on medicines…